Navigation Links
Progen's Phase 2 Liver Cancer Trial Exceeds Efficacy Objective

- Phase 3 Patient Enrolment Planned for Second Half of 2007 -

BRISBANE, Australia, April 16, 2007 /PRNewswire-FirstCall/ -- Progen Pharmaceuticals Limited today announced the final stage 1 results of its Phase 2 trial of PI-88 in patients who had previously undergone surgical removal of liver cancer. The 48 week data demonstrated that 160 mg of PI-88 showed an improvement in disease-free rate, the primary endpoint, of 25 percent and prolonged the time to tumour recurrence (disease- free survival) from 27 to 48 weeks, or by 78 percent, building on the 30-week results announced in December 2006.

The first stage of the randomised, two-stage multi-centre Phase 2 trial was designed to determine the appropriate dosage and possible efficacy of PI- 88 in reducing tumour recurrence in liver cancer patients who had previously undergone surgical removal of the cancer. Patients in this stage of the Phase 2 trial were randomly assigned to one of three groups to receive either the standard of care (with no PI-88 treatment), 160 mg of PI-88, or 250 mg of PI- 88, over 36 weeks with a 12 week follow-up period.

    Summary of results

    -- Treatment with 160 mg of PI-88 increased the disease-free rate by

       approximately 25 percent, from 50 percent to 63 percent at 48 weeks

    -- Treatment with 160 mg of PI-88 increased the time to recurrence of

       disease (disease-free survival) by approximately 78 percent, from 27 to

       48 weeks

    -- The final results confirmed the trend identified in the 30-week

       assessment that PI-88 delayed the recurrence of disease and increased

       the likelihood that the patient would be disease free for a longer

       period

    -- The 160 mg dosing level of PI-88 revealed a strong safety and

       tolerability profile and few adverse events directly or possibly

       related to treatment

As the 160mg dose was well tolerated and showed
'"/>




Page: 1 2 3

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Progen Phase Liver Cancer Trial Exceeds Efficacy Objective
(Date:12/17/2014)... Ariz. , Dec. 17, 2014  Beamz ... state-of-the-art interactive music products, today announced that it ... a leading manufacturer and supplier of innovative prosthetic, ... As part of the agreement, RSL Steeper ... bundled solution specifically configured for use within UK ...
(Date:12/17/2014)... and RALEIGH, N.C. , Dec. ... LLC (CTMC), and Integrated Clinical Trial Services, LLC ... retention for clinical trials announce that they have ... Marketing Services (i-CTMS). i-CTMS will provide a broad ... pharmaceutical, biotechnology and medical device companies. ...
(Date:12/15/2014)... Research and Markets ( http://www.researchandmarkets.com/research/32cmct/inferior_vena ) ... Cava (IVC) Filters - Global Trends, Estimates and Forecasts, ... http://photos.prnewswire.com/prnh/20130307/600769 Global Inferior Vena ... million by 2016. The North America ... value while Europe claims approximately ...
Breaking Medicine Technology:Beamz Interactive, Inc. Signs UK Distribution Agreement with RSL Steeper Limited 2Beamz Interactive, Inc. Signs UK Distribution Agreement with RSL Steeper Limited 3Integrated Clinical Trial Services and Clinical Trial Marketing Communications Form Joint Venture 2Integrated Clinical Trial Services and Clinical Trial Marketing Communications Form Joint Venture 3Inferior Vena Cava (IVC) Filters - Global Trends, Estimates and Forecasts, 2012-2018 2Inferior Vena Cava (IVC) Filters - Global Trends, Estimates and Forecasts, 2012-2018 3Inferior Vena Cava (IVC) Filters - Global Trends, Estimates and Forecasts, 2012-2018 4
... Genomic Health, Inc. (Nasdaq: GHDX ) today ... to study early-stage renal cell carcinoma prognosis, which demonstrated a ... patient population.  The study, which will be presented in an ... at the ASCO annual meeting in Chicago , could ...
... China , June 4 /PRNewswire-Asia-FirstCall/ -- Jiangbo,Pharmaceuticals, Inc. (OTC Bulletin ... in China , today,announced that the Company has received approval to ... , , ... common stock will begin trading on the NASDAQ,Global Market on Tuesday, ...
Cached Medicine Technology:Genomic Health Announces Results From the Largest Genomic Analysis of Localized Clear Cell Renal Carcinoma at American Society of Clinical Oncology (ASCO) Annual Meeting 2Genomic Health Announces Results From the Largest Genomic Analysis of Localized Clear Cell Renal Carcinoma at American Society of Clinical Oncology (ASCO) Annual Meeting 3Genomic Health Announces Results From the Largest Genomic Analysis of Localized Clear Cell Renal Carcinoma at American Society of Clinical Oncology (ASCO) Annual Meeting 4Genomic Health Announces Results From the Largest Genomic Analysis of Localized Clear Cell Renal Carcinoma at American Society of Clinical Oncology (ASCO) Annual Meeting 5Jiangbo Pharmaceuticals, Inc. Receives Approval to List on the NASDAQ Global Market 2Jiangbo Pharmaceuticals, Inc. Receives Approval to List on the NASDAQ Global Market 3
(Date:12/17/2014)... Project Veritas is releasing a video ... MIT economist and Obamacare architect Jonathan Gruber to public ... the interview, which is being distributed on YouTube. , ... mislabeling in the Affordable Care Act in order to ... billion dollar per year tax grab. , “President Obama ...
(Date:12/17/2014)... -- Greater participation in music classes may benefit children,s ... kids in the nonprofit Harmony Project, which provides music ... Over two years, children who actively participated in ... processes speech and reading, compared to those with lower ... participation in music classes occurred in the same areas ...
(Date:12/15/2014)... Cancer researchers have just published an important new report ... pleural mesothelioma. Surviving Mesothelioma has just posted an article ... to read it now. , Doctors at Harvard, ... York’s Langone Medical Center performed complete genetic analyses on ... effort to pinpoint the genes that are most likely ...
(Date:12/15/2014)... 15, 2014 OutMarket , a ... “ Social Media Cheat Sheets ,” a guide that ... drives results on the top ten social media networks. ... helps drive awareness, engagement, and customer service. It can ... make an impact on new networks and weather constantly ...
(Date:12/15/2014)... Kathy McAfee, America's Marketing Motivator, was ... in the category of Best Blog 2014. McAfee received ... weekly career blog Networking Ahead which combines ... elevate their talent and influence through better networking, leadership ... book Networking Ahead for Business, has been motivating readers ...
Breaking Medicine News(10 mins):Health News:Project Veritas: James O’Keefe Interviews the Man Who Discovered Jonathan Gruber Videos 2Health News:Music Classes Boost Language Skills, Study Says 2Health News:New Study Reveals Genetic Mutations That May Trigger Mesothelioma, According to Surviving Mesothelioma 2Health News:OutMarket Releases Cheat Sheets for Social Media Marketing 2Health News:OutMarket Releases Cheat Sheets for Social Media Marketing 3Health News:Kathy McAfee, America’s Marketing Motivator, Wins Best Blog from Women World Awards 2
... a new business to battle the rising costs of making funeral arrangements ... in these difficult economic times, for families to try to cut costs ... ... -- Grief Counseling Services (GCS), located in New York, recently announced the ...
... launch of new professional massage therapy marketing tool and search directory ... ... Atlanta, GA (PRWEB) February 18, 2009 -- This new membership based ... therapists in their city and post their profiles to promote their ...
... With sexual activity among adolescents in the United ... and reports of up to 25 percent of all ... researchers and public health officials are looking for those ... an article published in the April 2009 issue of ...
... provide trauma relief ,to both sides of the conflict ... team plans a training of health and mental health ... its kind working in both Israel and Gaza. ... for Mind-Body Medicine,s groundbreaking model which teaches self-care techniques ...
... Feb. 23 Campaign for America,s Future co-director ... Mishel and Center for Economic and Policy Research ... statement after participating in President Obama ,s summit ... ROGER HICKEY, DEAN BAKER AND LAWRENCE ...
... non-profit LENA(TM) Foundation, which develops technology for the improved ... two case studies showing how the breakthrough LENA system ... LENA software enables the clinician to measure adult word ... hourly intervals over the course of an entire day. ...
Cached Medicine News:Health News:Grief Counseling Services Battles Rising Costs of Funeral Expenses 2Health News:Grief Counseling Services Battles Rising Costs of Funeral Expenses 3Health News:MassageLinkUp.com Announces New Massage Directory for Professional Massage Therapists 2Health News:Sexual lyrics in popular songs linked to early sexual experiences 2Health News:Paving the Way for Peace in the Middle East with Mind-Body Skills 2Health News:Paving the Way for Peace in the Middle East with Mind-Body Skills 3Health News:Paving the Way for Peace in the Middle East with Mind-Body Skills 4Health News:Progressive Leaders at White House Summit Today Underscore Need for Health Care Reform 2Health News:LENA Foundation Technology Measures Effectiveness of Autism Therapy 2Health News:LENA Foundation Technology Measures Effectiveness of Autism Therapy 3
... you to scan every beating heart at any ... possible. A scanner using two X-ray sources ... provides one-stop diagnosis in acute care; even with ... Combined with the Cardiac Engine, a unique combination ...
... can code the charge while completing a chart ... away from office, both directly feeding the charge ... Encounter Form/Superbill, data entry can be done with ... payments are posted by reflecting open item charges, ...
... lens incorporate 3 mirrors angled at 76°, 66° ... anterior chamber as well as central and peripheral ... mirrors are accurately angled and spaced 120° apart ... The central portion of the lens also provides ...
The Mid Field 30° lens has a bi-concave design to provide a wider field of view with a 30 degree offset image....
Medicine Products: